- Home
- TNYA vs AMRN Comparison
TNYA vs AMRN Comparison
Compare TNYA & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNYA
- AMRN
- Stock Information
- Founded
- TNYA 2016
- AMRN 1989
- Country
- TNYA United States
- AMRN Ireland
- Employees
- TNYA N/A
- AMRN N/A
- Industry
- TNYA Medicinal Chemicals and Botanical Products
- AMRN Biotechnology: Pharmaceutical Preparations
- Sector
- TNYA Health Care
- AMRN Health Care
- Exchange
- TNYA Nasdaq
- AMRN Nasdaq
- Market Cap
- TNYA 326.0M
- AMRN 302.0M
- IPO Year
- TNYA 2021
- AMRN 1993
- Fundamental
- Price
- TNYA $1.43
- AMRN $16.81
- Analyst Decision
- TNYA Strong Buy
- AMRN Strong Sell
- Analyst Count
- TNYA 5
- AMRN 1
- Target Price
- TNYA $8.60
- AMRN $12.00
- AVG Volume (30 Days)
- TNYA 4.7M
- AMRN 142.8K
- Earning Date
- TNYA 11-06-2025
- AMRN 10-29-2025
- Dividend Yield
- TNYA N/A
- AMRN N/A
- EPS Growth
- TNYA N/A
- AMRN N/A
- EPS
- TNYA N/A
- AMRN N/A
- Revenue
- TNYA N/A
- AMRN $219,361,000.00
- Revenue This Year
- TNYA N/A
- AMRN N/A
- Revenue Next Year
- TNYA N/A
- AMRN N/A
- P/E Ratio
- TNYA N/A
- AMRN N/A
- Revenue Growth
- TNYA N/A
- AMRN N/A
- 52 Week Low
- TNYA $0.36
- AMRN $7.08
- 52 Week High
- TNYA $4.01
- AMRN $20.90
- Technical
- Relative Strength Index (RSI)
- TNYA 41.71
- AMRN 45.88
- Support Level
- TNYA $1.65
- AMRN $19.39
- Resistance Level
- TNYA $2.02
- AMRN $20.90
- Average True Range (ATR)
- TNYA 0.16
- AMRN 0.98
- MACD
- TNYA -0.07
- AMRN -0.26
- Stochastic Oscillator
- TNYA 0.00
- AMRN 0.00
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.